CoChat

Exendin-4 Modulates Diabetes Onset in Nonobese Diabetic Mice

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Activation of the glucagon-like peptide-1 receptor (GLP-1R) is associated with expansion of β-cell mass due to stimulation of cell proliferation and induction of antiapoptotic pathways coupled to β-cell survival. Although the GLP-1R agonist Exenatide (exendin-4) is currently being evaluated in subjects with type 1 diabetes, there is little information available about the efficacy of GLP-1R activation for prevention of experimental type 1 diabetes. We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 μg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes. Ex-4 treatment for 26 wk (2 μg twice daily) initiated at 4 wk of age delayed the onset of diabetes (P = 0.007). Ex-4-treated mice also exhibited a significant reduction in insulitis scores, enhanced β-cell mass, and improved glucose tolerance. Although GLP-1R mRNA transcripts were detected in spleen, thymus, and lymph nodes from nonobese diabetic mice, Ex-4 treatment was not associated with significant changes in the numbers of CD4+ or CD8+ T cells or B cells in the spleen. However, Ex-4 treatment resulted in an increase in the number of CD4+ and CD8+ T cells in the lymph nodes and a reduction in the numbers of CD4+CD25+Foxp3+ regulatory T cells in the thymus but not in lymph nodes. These findings demonstrate that sustained GLP-1R activation in the absence of concomitant immune intervention may be associated with modest but significant delay in diabetes onset in a murine model of type 1 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/en.2007-1137

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. Masur, 2004, Glucagon-like peptide-1 (GLP-1) is not only an important incretin hormone but also a modulator of the cellular immune system., Diabetes, 53, A49

Cited by

See all 110

Metadata

Authors
Hadjiyanni, I., Baggio, L. L., Poussier, P., & Drucker, D. J.
Affiliations
  • Mount Sinai Hospital (CA)
  • Sunnybrook Health Science Centre (CA)
Corresponding author
Drucker, Daniel J.
Venue
Endocrinology
Published
2007-12-06
Volume
149
Issue
3
Pages
1338-1349
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2172277730
Cited by
110
References
34
Citations by year
2026: 3 · 2025: 2 · 2024: 5 · 2023: 1 · 2022: 7 · 2021: 3 · 2020: 2 · 2019: 9 · 2018: 3 · 2017: 2 · 2016: 5 · 2015: 2 · 2014: 9 · 2013: 11 · 2012: 10
FWCI
5.02
Type
journal article
Language
en
Open access
Locations
  • Endocrinology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
exendin-4, GLP-1 receptor, type 1 diabetes prevention, NOD mice, insulitis, beta-cell mass, glucose tolerance, regulatory T cells, CD4+ T cells, CD8+ T cells, diabetes onset
MeSH terms
Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Diabetes Mellitus, Experimental, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Hypoglycemic Agents, Lymph Nodes, Peptides, Spleen, Venoms, CD4-Positive T-Lymphocytes, Mice, Inbred NOD, Receptors, Glucagon, CD8-Positive T-Lymphocytes, Disease Progression, Insulin-Secreting Cells, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exendin-4 Modulates Diabetes Onset in Nonobese Diabetic Mice. https://app.cochat.ai/papers/10.1210/en.2007-1137
The paper
Hadjiyanni, I., Baggio, L. L., Poussier, P., & Drucker, D. J. (2008). Exendin-4 Modulates Diabetes Onset in Nonobese Diabetic Mice. Endocrinology. https://doi.org/10.1210/en.2007-1137

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.